MindMaze and The Royal Buckinghamshire Hospital pioneer first U.K. location-based digital therapeutic solution for brain repair

Published: Oct. 14, 2021 at 5:00 AM EDT

LONDON and BALTIMORE, Oct. 14, 2021 /PRNewswire/ -- MindMaze Healthcare, the category leader in the multibillion-dollar digital neurotherapeutics market, today announced the first U.K. partnership for its novel MindPod platform to target cognitive and motor restoration in stroke patients with The Royal Buckinghamshire Hospital (RBH), based in Aylesbury.

MindMaze
MindMaze

MindPod is the world's first immersive neuro-animation experience – a unique form of location-based digital therapeutic that focuses on brain repair through high intensity and high dose complex exploratory movements. The MindPod is an immersive location-based animated gaming environment that includes customized sound, lighting and movement tracking. Based on technology developed by Johns Hopkins University School of Medicine's Department of Neurology, it is an evidence-based, protocolized, FDA-listed, and CE-Marked neurorestorative solution.

RBH represents MindMaze's first U.K. hospital installation for MindPod that targets stroke, based on a recently completed study that showed that it doubles the effectiveness of conventional rehabilitation in the upper limbs during the sub-acute phase [1.]. MindPod uses universal principles of brain repair; ongoing trials are using the same immersive room for Parkinson's disease, traumatic brain injury, dementia and healthy ageing, which attests to its potential for more general use in neurological disease and injury.

"MindPod is a complex-movement based exploration that affords a 100% immersive experience for patients. It allows us to take full advantage of a unique but short window of opportunity to repair the nervous system after a stroke," said John Krakauer, M.A., M.D., Professor of Neurology, Johns Hopkins University School of Medicine and Chief Medical Advisor to MindMaze. "It is a Pixar-level experience which recreates the enriched environments that neuroscience has shown to be beneficial in animal models."

Chris Campbell, Managing Director of RBH, stated, "RBH is a world leader in providing effective, evidence-based therapies for patients with neurological injury. Our partnership with MindMaze demonstrates our commitment to lead in the implementation of novel technologies in neurorestoration. We are excited about offering MindPod to patients for the first time in routine clinical practice in the U.K.. Not only is MindPod uniquely effective, it is a therapy that fits well into our existing treatment pathways, meets an unmet clinical need, and is patient-driven, enjoyable and cost-effective. We look forward to continuing to partner with MindMaze to accelerate the adoption of their world-class therapies into clinical practice in order to deliver outstanding outcomes for all patients."

Ali Jamous, M.D., Medical Director at RBH, said, "MindPod represents nothing less than a revolution in the treatment of stroke. In the U.K. 100,000 people have a stroke annually – that is one stroke every five minutes – yet only 10% of these people fully recover. Neuro-restoration of the arm is needed in 80% of stroke patients. Initial feedback from our patients is incredibly exciting: following a devastating neurological event, patients enjoy MindPod, they become fully engaged and motivated to continue the therapy as they lose themselves in the experience. MindPod gives them confidence to temporarily forget what they have lost, and instead explore what movements they can make, noticeably improving their motor function day by day as a high dose intervention that simply isn't feasible with comparably intensive levels of conventional rehabilitation."

MindPod is the subject of many clinical trials worldwide, including six studies on its effects in various stages of stroke recovery. MindPod has recently demonstrated doubled efficacy in a randomised trial treating the sub-acute phase of stroke compared to conventional rehabilitation[1]. MindPod has also successfully been piloted to enhance cognitive and functional wellness in a community setting for the healthy elderly[2], and an ongoing clinical trial is examining the improvement of motor and cognitive functions in Parkinson's disease[3]. Another study, funded by the U.S. Department of Defense, is looking at the efficacy of MindPod on older traumatic brain injury patients to slow progression to dementia; researchers are also exploring its use in motor recovery in hands and fingers for cervical spinal cord injury and in mild-to-moderate multiple sclerosis.

About MindMaze
MindMaze is a global leader in digital neuro-therapeutics (DTx) solutions with a mission to accelerate the brain's ability to recover, learn and adapt. With over a decade of work at the intersection of neuroscience, bio-sensing, engineering, mixed reality and artificial intelligence, its healthcare division is addressing some of the most challenging problems in neurology, including stroke, Alzheimer's disease and Parkinson's disease, by creating the a universal platform for brain health and recovery and unique digital therapeutic interventions. MindMaze's pioneering FDA cleared and CE marked neuro-digital therapeutics accelerate patients' recovery from many critical neurological conditions. Founded in 2012 by CEO Dr Tej Tadi, MindMaze is the first Swiss Unicorn with offices in Lausanne, Baltimore, London, Paris and Mumbai.
For more information, please visit www.mindmaze.com.

About The Royal Buckinghamshire Hospital
The Royal Buckinghamshire Hospital is a centre for high-intensity rehabilitation and complex nursing care in Aylesbury, U.K. Providing a state of the art facility in a historical, landmark building in the centre of Aylesbury, staffed by specialists, the service is well equipped to support patients with their recovery and rehabilitation.

[1] Comparing a novel neuroanimation experience to conventional therapy for high- dose, intensive upper-limb training in subacute stroke: The SMARTS2 randomized trial https://journals.sagepub.com/doi/10.1177/15459683211000730 https://clinicaltrials.gov/ct2/show/NCT02292251

[2] Carlson, M. (ongoing) Stimulation With Intricate Movements (SWIM) study. Aims to assess the feasibility and short-term impact of an immersive, interactive computer game, called Bandit the Dolphin, on the cognitive and functional health of aging adults living in the community. https://www.carlsonlab.org/copy-of-swim-study

[3] Feasibility and efficacy of an immersive virtual reality software in Parkinson's disease patients https://clinicaltrials.gov/ct2/show/nct04699617

View original content to download multimedia:

SOURCE MindMaze

The above press release was provided courtesy of PRNewswire. The views, opinions and statements in the press release are not endorsed by Gray Media Group nor do they necessarily state or reflect those of Gray Media Group, Inc.